Description:
This is a Phase 1/2, open-label, multicenter, sequential dose-escalation study to evaluate
the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of ZN-e4
administered orally in subjects with advanced non-small cell lung cancer (NSCLC) with
activating EGFR mutations who have progressed while on treatment with an EGFR tyrosine kinase
inhibitor (TKI) agent (other lines of treatment are allowed, except for other epidermal
growth factor receptor inhibitors [EGFRis]) for Phase 1; and for Phase 2, subjects who have
T790M+ and are osimertinib naïve (Cohort 1), and also those who have not been treated with an
EGFR Inhibitor (EGFRi) (Cohort2).
Title
- Brief Title: A Study of ZN-e4 in Subjects With Epidermal Growth Factor Receptor Mutated Non-Small Cell Lung Cancer
- Official Title: A Phase 1/2 Open Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of ZN-e4 (KP-673) in Patients With Advanced Non-Small Cell Lung Cancer With Activating Epidermal Growth Factor Receptor (EGFR) Mutations
Clinical Trial IDs
- ORG STUDY ID:
ZN-e4-001
- NCT ID:
NCT03446417
Conditions
- Carcinoma, Non-Small-Cell Lung
Interventions
Drug | Synonyms | Arms |
---|
ZN-e4 | | Phase 1 |
Purpose
This is a Phase 1/2, open-label, multicenter, sequential dose-escalation study to evaluate
the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of ZN-e4
administered orally in subjects with advanced non-small cell lung cancer (NSCLC) with
activating EGFR mutations who have progressed while on treatment with an EGFR tyrosine kinase
inhibitor (TKI) agent (other lines of treatment are allowed, except for other epidermal
growth factor receptor inhibitors [EGFRis]) for Phase 1; and for Phase 2, subjects who have
T790M+ and are osimertinib naïve (Cohort 1), and also those who have not been treated with an
EGFR Inhibitor (EGFRi) (Cohort2).
Trial Arms
Name | Type | Description | Interventions |
---|
Phase 1 | Experimental | Up to 9 sequential dose escalation cohorts to determine maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) is identified. | |
Phase 2 | Experimental | MTD/RP2D in subjects:
Cohort 1: with T790M mutation in epidermal growth factor receptor (EGFR) gene, and are osimertinib naïve.
Cohort 2: EGFRm amenable to EGFR inhibitor therapy (eg, exon 19 del, L858R) and who have never been treated with EGFRis. | |
Eligibility Criteria
INCLUSION CRITERIA
- Age ≥ 18 years
- Histologically or cytologically confirmed metastatic or advanced inoperable diagnosis
of NSCLC
- Documented radiographic progression on the last treatment administered prior to
enrolling in the study.
- Phase 1 only: Confirmation that the tumor harbors an EGFR mutation known to be
associated with aberrations that are amenable to EGFRi therapy including but not
limited to: G719X, exon 19 deletion, exon 21 L858R, and L861Q. OR - Must have
experienced clinical benefit from an EGFRi,
- All acute toxic effects of any prior antitumor therapy resolved to Grade ≤1 or
baseline before the start of study drug dosing (with the exception of alopecia [any
grade permitted] and neurotoxicity [Grade 1 or 2 permitted]).
- Measurable disease meeting the criteria specified by RECIST v1.1
- Phase 2, Cohort 1 only: Subjects must have confirmation of tumor T790M mutation status
(confirmed positive) and are osimertinib naïve
- Phase 2, Cohort 2 only: EGFR aberrations that are amenable to EGFRi therapy, including
but not limited to: G719X, exon 19 deletion, exon 21 L858R, and L861Q, and be EGFRi
naïve
EXCLUSION CRITERIA
- Subjects who have received only neoadjuvant or adjuvant therapy for NSCLC.
- Phase 1 only: Treatment with an EGFRi within 7 days or 5 half-lives of the first dose
of study treatment, whichever is shorter.
- Phase 1 only: Cytotoxic chemotherapy, investigational agents, or any anticancer
therapy for the treatment of advanced NSCLC (other than EGFRi) within 21 days of the
first dose of study treatment.
- Prior treatment with immunotherapy within 3 months prior to the first dose of study
treatment.
- Radiotherapy within 28 days of first dose of study treatment; subjects given
palliative radiotherapy to peripheral sites (e.g., bone metastases) may enter the
study before 28 days have elapsed provided the radiated sites do not contain lesions
which may be used to evaluate response, and must have recovered from any acute,
reversible effects.
- Known or suspected central nervous system (CNS) metastases or leptomeningeal disease
(Phase 1 only). Subjects with previously treated brain or CNS metastases are eligible
provided that the subject has recovered from any acute effects of radiotherapy, does
not have brain metastasis related symptoms, is not requiring systemic steroids for at
least 2 weeks prior to study drug administration, and any whole brain radiation
therapy was completed at least 4 weeks prior to study drug administration, or any
stereotactic radiosurgery (SRS) was completed at least 2 weeks prior to study drug
administration.
- Prior allogeneic bone marrow transplantation.
- History of a concurrent or second malignancy except for: adequately treated local
basal cell or squamous cell carcinoma of the skin; cervical carcinoma in situ;
superficial bladder cancer; breast carcinoma in situ; adequately treated Stage 1 or 2
cancer currently in complete remission; any other cancer that has been in complete
remission for ≥5 years.
Maximum Eligible Age: | N/A |
Minimum Eligible Age: | 18 Years |
Eligible Gender: | All |
Healthy Volunteers: | No |
Primary Outcome Measures
Measure: | Observed dose limiting toxicities |
Time Frame: | 1 Cycle (21 days) |
Safety Issue: | |
Description: | |
Secondary Outcome Measures
Measure: | Safety and tolerability as measured by incidence of treatment emergent adverse events |
Time Frame: | Through study completion, approximately 2 years |
Safety Issue: | |
Description: | |
Details
Phase: | Phase 1/Phase 2 |
Primary Purpose: | Interventional |
Overall Status: | Recruiting |
Lead Sponsor: | Zeno Pharmaceuticals, Inc. |
Last Updated
January 22, 2021